Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of IDH Mutation and Adjuvant Chemo(radio)therapy on Survival Outcome in Grade II/III Astrocytoma

NCT06620926 is registered in ClinicalTrials.gov with asmaa salama ibrahim as lead sponsor.

NCT NCT06620926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06620926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of IDH Mutation and Adjuvant Chemo(radio)therapy on Survival Outcome in Grade II/III Astrocytoma
Lead sponsor
asmaa salama ibrahim
Phase
Observational
Overall status
Completed
Start date
January 1, 2018
Completion date
December 30, 2021
Enrollment
811 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytic tumors, astrocytoma, astrocytoma of brain